GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD <li /> Additional ...